Skip to content
Biodatica
Start free

Kind Pharmaceuticals LLC

Guangzhou, Guangdong

OncologyPhase III
Compare Sign in to watch

What changed

Phase III trial registered: A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)

3mo agoTrial registeredMar 27, 2026Source filing (opens the source filing in a new tab)

Momentum

92no change

Momentum 92 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

672 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Dec 1, 2027

    Cancer-Related Anemia · NOT_YET_RECRUITING · sponsor: Kind Pharmaceuticals LLC · A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy

    ClinicalTrials.gov · NCT06075043 (opens the source filing in a new tab)

  2. Trial

    PHASE3 registered

    Dec 3, 2025

    Anemia Due to Chronic Kidney Disease · RECRUITING · sponsor: Kind Pharmaceuticals LLC · A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)

    ClinicalTrials.gov · NCT07487727 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Mar 14, 2025

    Myelodysplastic Syndromes · RECRUITING · sponsor: Kind Pharmaceuticals LLC · A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

    ClinicalTrials.gov · NCT06304103 (opens the source filing in a new tab)

  4. Trial

    PHASE2 registered

    May 27, 2024

    β -Thalassemia · RECRUITING · sponsor: Kind Pharmaceuticals LLC · A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia

    ClinicalTrials.gov · NCT06302491 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Oct 5, 2022

    Advanced or Metastatic Breast Cancer · RECRUITING · sponsor: Kind Pharmaceuticals LLC · A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

    ClinicalTrials.gov · NCT05187832 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources